Anzeige
Mehr »
Login
Dienstag, 26.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
500% Potenzial: Warum Analysten von diesem Uran-Explorer begeistert sind!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
699 Leser
Artikel bewerten:
(2)

Vimian Group Acquires Supplier of Veterinary Surgical Products in New Zealand and Australia

Finanznachrichten News

STOCKHOLM, SE / ACCESSWIRE / February 3, 2022 / Vimian Group (STO:VIMIAN)

Vimian Group has today signed an agreement to acquire Kahu Vet Group ("Kahuvet"), a supplier of veterinary surgical products in New Zealand and Australia. The acquisition represents a milestone in Vimian's strategy to expand its geographical presence and establish direct sales in selected key and underpenetrated markets. Kahuvet is a fast-growing company with revenues of around EUR 8.5 million in 2021.

Vimian's MedTech segment Movora has today signed an agreement to acquire Kahuvet. Kahuvet is a New Zealand-based supplier of veterinary products in New Zealand and Australia. Established in 2010, the company has a broad offering of veterinary orthopedic implants, surgical instruments, equipment as well pharmaceuticals and consumables. The majority of products are sold under Kahuvet's own brand Knight Benedikt to more than 700 veterinary clinics in New Zealand and Australia. In addition, Kahuvet offers training for advanced surgical procedures in its own educational center. The company has 18 employees based in Australia and New Zealand, and the two founding partners will continue to lead Kahu Vet Group as part of Vimian.

"The acquisition of Kahuvet represents a milestone in our strategy to expand our geographical presence and establish direct sales in key, underpenetrated markets. Through Kahuvet we gain a strong local footprint and a can sell our full MedTech product portfolio locally with improved customer service, shorter delivery times and a more efficient supply chain. Kahuvet is a fast-growing company with 35 percent revenue growth over the past year, and we're excited to work together with this commercially driven team, says Guy Spörri, Co-CEO of Vimian's MedTech segment Movora.

Kahuvet had revenues of around EUR 8.5 million in 2021 and an EBITDA of around EUR 1.6 million. The acquisition will have a marginal impact on Vimian Group's earnings per share in the current financial year. The purchase price consists of an upfront payment of EUR 12.1 million financed with available funds, and potential earn-out payments of up to EUR 10.4 million subject to financial performance over three years, part of which the selling management has committed to reinvest in Vimian shares.

Kahuvet is expected to be consolidated into Vimian Group's MedTech segment on or around 1 March 2022.

For further information, please contact:

Maria Dahllöf Tullberg
Head of IR & Communications
maria.tullberg@vimian.com
+46 736 26 88 86

About Vimian

Vimian is a global, fast-growing group of innovation-driven companies with a shared passion for making a positive impact through improving animal health. Together, we put science, technology and our customers' needs at the centre of everything we do to deliver effective solutions to veterinary professionals, labs and pet parents around the world. We bring together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. Our group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to our networks, expertise, infrastructure and capital to accelerate innovation and growth. We are as passionate about supporting leadership within our existing businesses, as we are about welcoming new partners to the Vimian family - together helping us make an even greater impact by improving animal health. Headquartered in Stockholm, Sweden, Vimian and our family of companies reach over 15,000 customers in +150 markets, employ more than 450 people and have a combined annual turnover of approximately EUR 140 million. FNCA Sweden AB is appointed the Company's Certified Adviser, info@fnca.se , +46 (0) 8-528 00 399. For more information, please visit: www.vimian.com.

Attachments

Vimian Group acquires supplier of veterinary surgical products in New Zealand and Australia

SOURCE: Vimian Group



View source version on accesswire.com:
https://www.accesswire.com/687088/Vimian-Group-Acquires-Supplier-of-Veterinary-Surgical-Products-in-New-Zealand-and-Australia

© 2022 ACCESSWIRE
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.